查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813989

遺傳性癌症檢測市場規模、佔有率和趨勢分析報告：按癌症類型、技術、檢測類型、最終用途、地區和細分市場預測，2025-2033 年

Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology, By Test Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

遺傳性癌症檢測市場摘要

預計 2024 年全球遺傳性癌症檢測市值為 46.7 億美元，2033 年將達到 144.5 億美元，2025 年至 2033 年的複合年成長率為 13.76%。

由於癌症檢測基因檢測技術的進步、與精準醫療的結合以及公眾和政府措施的提高，對遺傳性癌症檢測的需求正在增加。

此外，癌症盛行率的上升也推動了遺傳性癌症檢測的普及。根據美國國家癌症美國的數據，遺傳性癌症是由基因變異引起的，佔所有其他癌症類型的10%。遺傳性癌症透過遺傳性突變遺傳，導致基因缺陷，並遺傳給後代，增加罹癌風險。因此，大眾對早期發現和緩解症狀的需求日益成長。

基因檢測技術的進步，尤其是次世代定序儀(NGS) 技術，顯著提高了遺傳性癌症檢測的準確性和可近性。傳統方法效率低且耗時，可能會延長後續治療時間。次世代定序儀(NGS) 就是這樣一種檢測技術，它可以在短時間內同時檢測單一基因內數百萬個 DNA 拷貝，從而能夠在一次檢測中全面分析多個基因和突變。例如，Illumina 的 NovaSeq X 平台可以分析大規模定序數據，並提供用於診斷疾病狀態的高通量定序。基因檢測的技術創新有助於早期發現遺傳性癌症突變，指導個人化治療方案，並以非侵入性方式監測疾病進展。因此，透過整合早期癌症檢測系統，癌症醫學將觀點從傳統檢測方法轉向先進技術。

基因檢測在精準醫療中發揮著至關重要的作用，它能夠識別影響癌症風險和治療結果的基因突變。精準醫療的根本基礎是了解特定基因變異對癌症的影響。精準醫療透過根據患者的個別特徵量身定做檢測和治療來改變癌症治療。它可以識別癌症高風險族群，並及早干預以降低風險。它還可以幫助及早發現某些癌症，並準確診斷特定癌症類型。此外，它還可以持續評估治療效果並進行調整以改善結果。這種個人化方法透過從「一刀切」的治療方法轉向針對患者的有針對性的治療方法，提高了癌症患者的生存率和生活品質。

公眾和政府主導的意識提昇在擴大遺傳性癌症檢測方面發揮關鍵作用。例如，作為一項政府計劃，美國國立衛生研究院 (NIH) 於 2024 年 2 月啟動了癌症篩檢研究網路 (CSRN)，這是一個臨床試驗網路，旨在評估新的癌症篩檢技術，推出多癌症種檢測 (MCD)。該舉措重點關注癌症的早期發現，以便在治療更有效的時期進行，從而支持拜登-哈里斯政府的「癌症登月計畫」。

美國國立衛生研究院 (NIH) 也持續致力於透過預防和篩檢五大癌症（乳癌、子宮頸癌、大腸癌、肺癌和攝護腺癌）來挽救生命。截至 2024 年 12 月，這些努力已挽救了 475 萬人的生命。此外，多項宣傳活動和線上資源也提高了公眾對遺傳性癌症檢測的認知。這些共同努力旨在教育個人、鼓勵及時檢測並支持預防性護理，最終降低癌症發病率並改善不同人群的預後。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 遺傳性癌症檢測市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場前景。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 遺傳性癌症檢測市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章遺傳性癌症檢測市場：癌症估計與趨勢分析

  • 細分儀表板
  • 遺傳性癌症檢測市場：癌症變異分析
  • 遺傳性癌症檢測市場規模及趨勢分析（依癌症類型，2021-2033）
  • 2021-2033年遺傳性癌症檢測市場收益估計與預測
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 卵巢癌
  • 攝護腺癌
  • 胃癌
  • 黑色素瘤
  • 肉瘤
  • 子宮癌
  • 胰臟癌
  • 其他

第5章：遺傳性癌症檢測市場：技術評估與趨勢分析

  • 2024年及2033年技術市場佔有率
  • 細分儀表板
  • 全球遺傳性癌症檢測市場技術展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 細胞遺傳學
  • 生化
  • 分子檢測

第6章：遺傳性癌症檢測市場：檢測類型估計與趨勢分析

  • 2024 年和 2033 年測試類型市場佔有率
  • 細分儀表板
  • 全球測試類型市場展望（按數量）
  • 2021年至2033年市場規模、預測與趨勢分析
  • 預測測試
  • 診斷測試

7. 遺傳性癌症檢測市場：最終用途估計與趨勢分析

  • 2024年和2033年的最終用途市場佔有率
  • 細分儀表板
  • 全球最終用途市場：最終用途展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 診斷中心
  • 醫院
  • 診所

第8章：遺傳性癌症檢測市場：區域估計和趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2021-2033年：
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Bio-Rad Laboratories
    • CSL Ltd
    • Qiagen NV
    • Danaher Corporation
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
Product Code: GVR-4-68040-588-5

Hereditary Cancer Testing Market Summary

The global hereditary cancer testing market size was estimated at USD 4.67 billion in 2024 and is projected to reach USD 14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine, and growing awareness through public and government initiatives.

In addition, the rising prevalence of cancer diseases amongst the population is augmenting the adoption of hereditary cancer testing. According to the National Cancer Institute, hereditary cancer, caused by inherited genetic changes, accounts for 10% of all other cancer types. Hereditary cancer is passed on to coming generations as defective familial mutations in the genes, concomitantly increasing the risk of cancer. Hence, there arises a growing need among the people for early detection and for mitigating cancer symptoms.

Advancements in genetic testing technologies, particularly next-generation sequencing (NGS), have significantly improved the accuracy and accessibility of hereditary cancer testing. Traditional methods lack efficiency and are time-consuming, which may prolong the treatment duration thereafter. One such testing technology is the next-generation sequencing (NGS), which can simultaneously detect millions of copies of DNA in a gene within a short span of time, allowing comprehensive profiling of multiple genes and mutations in a single test. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of diseases. The innovations in genetic testing facilitate early detection of hereditary cancer mutations, guide personalized treatment plans, and monitor disease progression non-invasively. Thus, progress in oncology medicine by integration of early cancer detection systems is transforming the perspective to advanced technologies rather than traditional testing methods.

Hereditary testing plays a pivotal role in precision medicine by enabling the identification of genetic mutations that influence cancer risk and treatment response. The basis of precision medicine lies in understanding the effects of alterations in certain genes in cancer. Precision medicine is transforming cancer care to tailor tests and treatments based on individual patient characteristics. It helps identify people at high risk for cancer, allowing early interventions to reduce their risk. It also aids in detecting certain cancers at an early stage and ensures accurate diagnosis of specific cancer types. Additionally, it allows ongoing evaluation of how well a treatment is working, enabling adjustments to improve outcomes. This personalized approach improves survival rates and quality of life for cancer patients by moving beyond one-size-fits-all therapies to targeted, patient-specific care.

Growing awareness through public and government initiatives plays a crucial role in expanding hereditary cancer testing. Government efforts, for example, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), a clinical trials network aimed at evaluating emerging cancer screening technologies, including multi-cancer detection (MCD) tests. This initiative supports the Biden-Harris administration's Cancer Moonshot by focusing on identifying cancers earlier, when treatment is more effective.

The National Institutes of Health (NIH) is also working continuously in prevention and screening for five major types of cancer: breast, cervical, colorectal, lung, and prostate, in order to save lives. Due to its initiatives, as of December 2024, 4.75 million deaths have been averted. Furthermore, several campaigns and online resources have raised awareness among the people for hereditary cancer testing. These combined efforts aim to empower individuals with knowledge, encourage timely testing, and support preventive care, ultimately reducing cancer incidence and improving outcomes across diverse populations.

Global Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hereditary cancer testing market report based on cancer, technology, test type, end use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Stomach/Gastric Cancer
  • Melanoma
  • Sarcoma
  • Uterine Cancer
  • Pancreatic Cancer
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Cytogenetic
  • Biochemical
  • Molecular Testing
  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Predictive Testing
  • Diagnostic Testing
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostic Centers
  • Hospitals
  • Clinics
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Test Type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements of genetic testing in cancer detection
      • 3.2.1.2. Integration with precision medicine
      • 3.2.1.3. Growing awareness through public and government initiatives
      • 3.2.1.4. Rising prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs and limited insurance coverage
  • 3.3. Hereditary Cancer Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
  • 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
  • 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Lung Cancer
    • 4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Colorectal Cancer
    • 4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Cervical Cancer
    • 4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.10. Prostate Cancer
    • 4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.11. Stomach/Gastric Cancer
    • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.12. Melanoma
    • 4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.13. Sarcoma
    • 4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.14. Uterine Cancer
    • 4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.15. Pancreatic Cancer
    • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.16. Others
    • 4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Cytogenetic
    • 5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Biochemical
    • 5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Molecular Testing
    • 5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis

  • 6.1. Test type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Test type Market by Capacity Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Predictive Testing
    • 6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Testing
    • 6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global End Use Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Diagnostic Centers
    • 7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Hospitals
    • 7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Clinics
    • 7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/Reimbursement
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/Reimbursement
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/Reimbursement
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/Reimbursement
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/Reimbursement
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/Reimbursement
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Myriad Genetics, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Services benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Invitae Corporation
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Services benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Services benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. CSL Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Services benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Qiagen NV
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Services benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Danaher Corporation
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Services benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Thermo Fisher Scientific
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Services benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Abbott Laboratories
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Services benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. EUROFINS SCIENTIFIC
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Services benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. F. HOFFMANN-LA ROCHE LTD
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Services benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Illumina, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Services benchmarking
      • 9.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Hereditary cancer testing market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 4 North America Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 5 North America Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 6 North America Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 8 U.S Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 9 U.S Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 10 U.S Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 12 Canada Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 13 Canada Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 14 Canada Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 16 Mexico Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 17 Mexico Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 20 Europe Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 21 Europe Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 22 Europe Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 23 UK Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 24 UK Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 25 UK Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 26 UK Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Germany Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 28 Germany Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 30 Germany Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 31 France Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 32 France Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 33 France Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 34 France Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Italy Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 36 Italy Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 37 Italy Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 38 Italy Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Spain Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 40 Spain Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 41 Spain Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 42 Spain Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Denmark Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 44 Denmark Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 45 Denmark Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Sweden Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 48 Sweden Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 49 Sweden Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 50 Sweden Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Norway Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 52 Norway Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 53 Norway Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 54 Norway Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 55 Asia Pacific Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Japan Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 60 Japan Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 61 Japan Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 62 Japan Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 63 China Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 64 China Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 65 China Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 66 China Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 67 India Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 68 India Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 69 India Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 70 India Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Australia Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 72 Australia Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 Australia Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 74 Australia Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 75 South Korea Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 76 South Korea Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 South Korea Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 78 South Korea Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Thailand Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 80 Thailand Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 81 Thailand Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 82 Thailand Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Latin America Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 84 Latin America Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Latin America Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 86 Latin America Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 87 Brazil Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 88 Brazil Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Brazil Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 90 Brazil Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Argentina Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 92 Argentina Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 93 Argentina Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 94 Argentina Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 95 MEA Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 96 MEA Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 97 MEA Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 98 MEA Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 99 South Africa Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 100 South Africa Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 101 South Africa Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 102 South Africa Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 Saudi Arabia Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 104 Saudi Arabia Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 105 Saudi Arabia Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 106 Saudi Arabia Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 107 UAE Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 108 UAE Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 109 UAE Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 110 UAE Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)
  • Table 111 Kuwait Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 112 Kuwait Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 113 Kuwait Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 114 Kuwait Hereditary cancer testing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Hereditary cancer testing market: market outlook
  • Fig. 14 Hereditary cancer testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Hereditary cancer testing market driver impact
  • Fig. 20 Hereditary cancer testing market restraint impact
  • Fig. 21 Hereditary cancer testing market strategic initiatives analysis
  • Fig. 22 Hereditary cancer testing market: Cancer movement analysis
  • Fig. 23 Hereditary cancer testing market: Cancer outlook and key takeaways
  • Fig. 24 Hereditary cancer Testing market estimates and forecast, 2021 - 2033
  • Fig. 25 Hereditary cancer testing Market: Technology movement analysis
  • Fig. 26 Hereditary cancer testing market: Technology outlook and key takeaways
  • Fig. 27 Cytogenetic market estimates and forecasts, 2021 - 2033
  • Fig. 28 Biochemical market estimates and forecasts,2021 - 2033
  • Fig. 29 Molecular Testing market estimates and forecasts,2021 - 2033
  • Fig. 30 Hereditary cancer testing Market: Test Type movement analysis
  • Fig. 31 Hereditary cancer testing Market: Test Type outlook and key takeaways
  • Fig. 32 Predictive Testing market estimates and forecasts, 2021 - 2033
  • Fig. 33 Diagnostic Testing market estimates and forecasts, 2021 - 2033
  • Fig. 34 Hereditary cancer testing Market: End Use movement analysis
  • Fig. 35 Hereditary cancer testing market: End Use outlook and key takeaways
  • Fig. 36 Diagnostic Centers market estimates and forecasts, 2021 - 2033
  • Fig. 37 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 38 Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 39 Global Hereditary cancer testing market: Regional movement analysis
  • Fig. 40 Global Hereditary cancer testing market: Regional outlook and key takeaways
  • Fig. 41 Global Hereditary cancer testing market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America
  • Fig. 49 North America market estimates and forecasts, 2021 - 2033
  • Fig. 50 U.S.
  • Fig. 51 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 52 Canada
  • Fig. 53 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 54 Mexico
  • Fig. 55 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 56 Europe
  • Fig. 57 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 58 UK
  • Fig. 59 UK market estimates and forecasts, 2021 - 2033
  • Fig. 60 Germany
  • Fig. 61 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 62 France
  • Fig. 63 France market estimates and forecasts, 2021 - 2033
  • Fig. 64 Italy
  • Fig. 65 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 66 Spain
  • Fig. 67 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 68 Denmark
  • Fig. 69 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 70 Sweden
  • Fig. 71 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 72 Norway
  • Fig. 73 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 74 Asia Pacific
  • Fig. 75 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 76 China
  • Fig. 77 China market estimates and forecasts, 2021 - 2033
  • Fig. 78 Japan
  • Fig. 79 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 80 India
  • Fig. 81 India market estimates and forecasts, 2021 - 2033
  • Fig. 82 Thailand
  • Fig. 83 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 84 South Korea
  • Fig. 85 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 86 Australia
  • Fig. 87 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 88 Latin America
  • Fig. 89 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 90 Brazil
  • Fig. 91 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 92 Argentina
  • Fig. 93 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 94 Middle East and Africa
  • Fig. 95 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 96 South Africa
  • Fig. 97 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 98 Saudi Arabia
  • Fig. 99 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 100 UAE
  • Fig. 101 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 102 Kuwait
  • Fig. 103 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 104 Market share of key market players- Hereditary cancer testing market